Cimetropium

Summary

Cimetropium (CHEMBL2110773) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 358.5 Da · C21H28NO4+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110773
Name	Cimetropium
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	20054871
Molecular formula	C21H28NO4+
Molecular weight	358.5
InChIKey	QVVOZYKELHAIPX-MWGADRMYSA-N

SMILES: C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)CC5CC5

IUPAC name: [(1R,2R,4S,5S)-9-(cyclopropylmethyl)-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate

Also known as: Cimetropium cation, Cimetropium ion, CIMETROPIUM, cimetropium

Parent form; salt/anhydrous children: CHEMBL2105977

Patent coverage: 14 distinct patent families (27 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).